Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma

Gemcitabine (Gem)-based chemotherapy is one of the first-line treatments for pancreatic ductal adenocarcinoma (PDAC). However, its clinical effect is limited due to development of chemoresistance. Various naturally occurring compounds, including Berberine (BBR), provide an anti-cancer efficacy with...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuno, Keisuke, Xu, Caiming, Pascual-Sabater, Silvia, Tokunaga, Masanori, Han, Haiyong, Fillat, Cristina, Kinugasa, Yusuke, Goel, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611392/
https://www.ncbi.nlm.nih.gov/pubmed/36297310
http://dx.doi.org/10.3390/ph15101199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9611392/
https://www.ncbi.nlm.nih.gov/pubmed/36297310
http://dx.doi.org/10.3390/ph15101199

Ejemplares similares